Trial Profile
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Ph 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults With Asthma Inadequately Controlled on Inhaled Corticosteroid (MESOS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms MESOS
- Sponsors AstraZeneca
- 07 May 2022 Results of post-hoc exploratory analysis assessing profile baseline airway inflammation in patients with moderate-to-severe asthma,published in the Journal of Allergy and Clinical Immunology.
- 23 May 2018 Primary endpoint (Airway submucosal eosinophils) has not been met, according to the results presented at the 114th International Conference of the American Thoracic Society.
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.